S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Panbela Therapeutics (PBLA) News Today

$1.12
+0.01 (+0.90%)
(As of 02/23/2024 ET)
SourceHeadline
benzinga.com logoTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
benzinga.com - February 23 at 7:50 AM
MarketBeat logoContrasting NeuroSense Therapeutics (NASDAQ:NRSN) and Panbela Therapeutics (NASDAQ:PBLA)
americanbankingnews.com - February 16 at 3:22 AM
finance.yahoo.com logoPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
finance.yahoo.com - February 15 at 11:37 AM
globenewswire.com logoPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
globenewswire.com - February 15 at 8:00 AM
finance.yahoo.com logoPanbela Announces Closing of Approximately $9.0 Million Public Offering
finance.yahoo.com - February 1 at 9:59 AM
investing.com logoPanbela Therapeutics Inc (PBLA)
investing.com - January 31 at 8:53 AM
finanznachrichten.de logoPanbela Therapeutics, Inc.: Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
finanznachrichten.de - January 30 at 3:23 PM
benzinga.com logoWhat's Going On With Panbela Therapeutics Stock Today?
benzinga.com - January 30 at 10:23 AM
finance.yahoo.com logoAcceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
finance.yahoo.com - January 30 at 10:23 AM
msn.com logoPanbela Therapeutics, Processa Pharmaceuticals among healthcare movers
msn.com - January 29 at 1:25 PM
markets.businessinsider.com logoPanbela Therapeutics Prices $9 Mln Share Offering
markets.businessinsider.com - January 29 at 1:25 PM
investorplace.com logoWhy Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
investorplace.com - January 29 at 10:03 AM
marketwatch.com logoPanbela Therapeutics Shares Slide Premarket After Public Offering
marketwatch.com - January 29 at 8:24 AM
msn.com logoPanbela Therapeutics drops on $9M public offering
msn.com - January 29 at 8:24 AM
finance.yahoo.com logoPanbela Announces Pricing of Approximately $9.0 Million Public Offering
finance.yahoo.com - January 29 at 8:24 AM
msn.com logoWhat's Going On With Panbela Therapeutics Stock?
msn.com - January 26 at 8:06 PM
marketbeat.com logo
marketbeat.com - January 26 at 9:42 AM
finance.yahoo.com logoPanbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
finance.yahoo.com - January 25 at 8:36 AM
marketbeat.com logo
marketbeat.com - January 23 at 9:39 AM
marketwatch.com logoPanbela Therapeutics Touch 52-Week Low on Planned Public Offering
marketwatch.com - January 22 at 5:53 PM
marketbeat.com logo
marketbeat.com - January 18 at 1:07 PM
finance.yahoo.com logoPanbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
finance.yahoo.com - January 18 at 8:25 AM
marketbeat.com logo
marketbeat.com - January 18 at 6:05 AM
finance.yahoo.com logoPanbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
finance.yahoo.com - January 16 at 8:32 AM
morningstar.com logoPanbela Therapeutics' stock skyrockets after positive FDA news on child cancer treatment
morningstar.com - December 21 at 6:25 PM
finance.yahoo.com logoPanbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
finance.yahoo.com - December 21 at 1:24 PM
msn.com logoPanbela Therapeutics (PBLA) Stock Is Down 25%: What's Going On?
msn.com - December 20 at 7:21 PM
msn.com logoWhat In The World Is Going On With Panbela Therapeutics (PBLA) Stock?
msn.com - December 19 at 1:02 PM
realmoney.thestreet.com logoPanbela Therapeutics at Roth MKM, here's why
realmoney.thestreet.com - December 18 at 3:18 PM
msn.com logoWhat's Going On With Panbela Therapeutics (PBLA) Stock?
msn.com - December 18 at 3:18 PM
finanznachrichten.de logoPanbela Therapeutics, Inc.: Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
finanznachrichten.de - December 18 at 10:17 AM
finance.yahoo.com logoPanbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
finance.yahoo.com - December 18 at 10:17 AM
markets.businessinsider.com logoBuy Rating Affirmed for Panbela Therapeutics Following FDA Approval and Positive Trial Progress
markets.businessinsider.com - December 15 at 11:43 PM
finance.yahoo.com logoPanbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
finance.yahoo.com - December 4 at 12:21 PM
markets.businessinsider.com logoPositive Outlook for Panbela Therapeutics Backed by Buy Rating and Clinical Progress
markets.businessinsider.com - November 30 at 8:26 AM
finance.yahoo.com logoPanbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
finance.yahoo.com - November 29 at 10:37 AM
insidermonkey.com logoPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q3 2023 Earnings Call Transcript
insidermonkey.com - November 12 at 2:56 PM
finanznachrichten.de logoPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2023 Financial Results
finanznachrichten.de - November 10 at 10:26 AM
finance.yahoo.com logoPanbela Provides Business Update and Reports Q3 2023 Financial Results
finance.yahoo.com - November 9 at 6:33 PM
msn.com logoWhy Panbela Therapeutics (PBLA) Stock Is Nosediving
msn.com - November 3 at 4:03 PM
finance.yahoo.com logoPanbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
finance.yahoo.com - November 3 at 9:32 AM
markets.businessinsider.com logoNasdaq Surges Over 1%; US Initial Jobless Claims Increase To 217,000
markets.businessinsider.com - November 2 at 1:49 PM
benzinga.com logoWhy Is Cancer Firm Panbela Therapeutics Stock Trading Higher Today?
benzinga.com - November 2 at 1:49 PM
finance.yahoo.com logoPanbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
finance.yahoo.com - November 2 at 8:49 AM
finance.yahoo.com logoPanbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
finance.yahoo.com - October 31 at 9:49 AM
baystreet.ca logoPanbela Dwindles on Acceptance of Inhibitor
baystreet.ca - October 25 at 1:06 PM
finance.yahoo.com logoAcceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
finance.yahoo.com - October 25 at 1:06 PM
finance.yahoo.com logoPanbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
finance.yahoo.com - October 24 at 9:49 AM
finance.yahoo.com logoPanbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
finance.yahoo.com - September 26 at 10:17 AM
finance.yahoo.com logoPanbela to Present at the LD Micro Investor Conference
finance.yahoo.com - September 19 at 9:49 AM
Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.



PBLA Media Mentions By Week

PBLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PBLA
News Sentiment

0.00

0.46

Average
Medical
News Sentiment

PBLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PBLA Articles
This Week

1

2

PBLA Articles
Average Week

Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:PBLA) was last updated on 2/23/2024 by MarketBeat.com Staff